Search Results

There are 52335 results for: content related to: Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

  1. You have free access to this content
    Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 2, 15 January 2012, Pages: 300–311, Jerald P. Radich

    Version of Record online : 29 JUN 2011, DOI: 10.1002/cncr.26280

  2. You have free access to this content
    Practical management of patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Version of Record online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  3. Do we need more drugs for chronic myeloid leukemia?

    Immunological Reviews

    Volume 263, Issue 1, January 2015, Pages: 106–123, Tessa L. Holyoake and G. Vignir Helgason

    Version of Record online : 15 DEC 2014, DOI: 10.1111/imr.12234

  4. Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 9P2, September 2010, Pages: 77S–101S, Kamakshi V. Rao, Andrea Iannucci and Elias Jabbour

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.pt2.77S

  5. Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients

    Cell Proliferation

    Volume 48, Issue 4, August 2015, Pages: 486–496, Guangshan Tan, Lei Shi, Qiang Li and Mingjun Wang

    Version of Record online : 6 JUL 2015, DOI: 10.1111/cpr.12194

  6. You have free access to this content
    Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

    American Journal of Hematology

    Volume 86, Issue 9, September 2011, Pages: 811–819, Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli and Ayalew Tefferi

    Version of Record online : 17 AUG 2011, DOI: 10.1002/ajh.22097

  7. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry

    European Journal of Haematology

    Volume 87, Issue 2, August 2011, Pages: 157–168, Edgar Faber, Jan Mužík, Vladimír Koza, Eva Demečková, Jaroslava Voglová, Ĺudmila Demitrovičová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Tomáš Kozák, Elena Tóthová, Marie Jarošová, Ladislav Dušek and Karel Indrák

    Version of Record online : 15 JUL 2011, DOI: 10.1111/j.1600-0609.2011.01637.x

  8. You have free access to this content
    Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

    American Journal of Hematology

    Volume 87, Issue 11, November 2012, Pages: 1037–1045, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 23 OCT 2012, DOI: 10.1002/ajh.23282

  9. You have free access to this content
    Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: 242–249, Harry P. Erba

    Version of Record online : 30 JAN 2015, DOI: 10.1002/ajh.23902

  10. You have free access to this content
    How I treat newly diagnosed chronic myeloid leukemia in 2015

    American Journal of Hematology

    Volume 90, Issue 2, February 2015, Pages: 156–161, Carlo Gambacorti-Passerini and Rocco Piazza

    Version of Record online : 24 NOV 2014, DOI: 10.1002/ajh.23887

  11. Imatinib Mesylate, the First Molecularly Targeted Gene Suppressor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 22, Issue 10, October 2002, Pages: 1249–1265, Vanita K. Pindolia and Barbara J. Zarowitz

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.22.15.1249.33482

  12. You have full text access to this OnlineOpen article
    Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 69–81, Tim H. Brümmendorf, Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis and Carlo Gambacorti-Passerini

    Version of Record online : 8 SEP 2014, DOI: 10.1111/bjh.13108

  13. You have full text access to this OnlineOpen article
    Suboptimal responses in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 5, 1 March 2012, Pages: 1181–1191, Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes and Hagop Kantarjian

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26391

  14. Chronic Myelogenous Leukemia

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt008

  15. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

    Journal of Clinical Nursing

    Volume 19, Issue 9-10, May 2010, Pages: 1207–1218, Sara M Tinsley

    Version of Record online : 16 MAR 2010, DOI: 10.1111/j.1365-2702.2009.03167.x

  16. You have full text access to this OnlineOpen article
    Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

    American Journal of Hematology

    Volume 90, Issue 9, September 2015, Pages: 755–768, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Dong-Wook Kim, Hanna J. Khoury, Anna G. Turkina, Tim H. Brümmendorf, Ewa Matczak, Nathalie Bardy-Bouxin, Mark Shapiro, Kathleen Turnbull, Eric Leip and Jorge E. Cortes

    Version of Record online : 1 JUN 2015, DOI: 10.1002/ajh.24034

  17. You have free access to this content
    Risk and impact of tuberculosis in patients with chronic myeloid leukemia: A nationwide population-based study in Taiwan

    International Journal of Cancer

    Volume 136, Issue 8, 15 April 2015, Pages: 1881–1887, Chia-Jen Liu, Ying-Chung Hong, Chung-Jen Teng, Man-Hsin Hung, Yu-Wen Hu, Fan-Chen Ku, Yung-Tai Chen, Sheng-Hsuan Chien, Chiu-Mei Yeh, Tzeng-Ji Chen, Tzeon-Jye Chiou, Jyh-Pyng Gau and Cheng-Hwai Tzeng

    Version of Record online : 30 SEP 2014, DOI: 10.1002/ijc.29201

  18. You have free access to this content
    Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

    Cancer

    Volume 116, Issue 6, 15 March 2010, Pages: 1419–1430, Hagop M. Kantarjian, Jorge Cortes, Paul La Rosée and Andreas Hochhaus

    Version of Record online : 29 JAN 2010, DOI: 10.1002/cncr.24928

  19. You have free access to this content
    First-line therapy for chronic myeloid leukemia: Past, present, and future

    American Journal of Hematology

    Volume 84, Issue 5, May 2009, Pages: 287–293, Carolina Pavlovsky, Hagop Kantarjian and Jorge E. Cortes

    Version of Record online : 19 FEB 2009, DOI: 10.1002/ajh.21380

  20. Pharmacogenomics of Dasatinib (Sprycel™)

    Kinase Inhibitor Drugs

    Fei Huang, Edwin A. Clark, Pages: 365–402, 2009

    Published Online : 28 SEP 2009, DOI: 10.1002/9780470524961.ch15